Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1979 Nov;26(2):435–440. doi: 10.1128/iai.26.2.435-440.1979

Chemotaxigenesis and activation of the alternative complement pathway by encapsulated and non-encapsulated Cryptococcus neoformans.

K A Laxalt, T R Kozel
PMCID: PMC414633  PMID: 397927

Abstract

In the presence of serum, whole cells of encapsulated and non-encapsulated Cryptococcus neoformans generated a chemotactic response by neutrophils. Heat inactivation of serum ablated all chemotactic activity. Cryptococcal polysaccharide was not chemotaxigenic. Assays for alternative complement pathway activation such as depletion of alternative complement pathway factor B or electrophoretic conversion of factor B closely paralleled chemotaxis assays. Cells of encapsulated and non-encapsulated C. neoformans activated the alternative complement pathway, whereas cryptococcal polysaccharide was inactive. Failure of the capsular material to activate the alternative pathway was not due to serotype specificity because polysaccharide of several serotypes failed to achieve activation. The results suggest that chemotaxigenesis and alternative complement pathway activation are functions of the yeast cell wall. The results support our proposal that the cryptococcal capsul does not prevent potential opsonins from reaching binding and activation sites at the yeast cell wall or the release of biologically active soluble cleavage products into the surrounding medium; however, cell wall-bound cleavage products remain bound to the cell wall beneath the capsule. Therefore, they are unable to participate as opsonins in phagocytosis.

Full text

PDF
435

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allan R. B., Wilkinson P. C. A visual analysis of chemotactic and chemokinetic locomotion of human neutrophil leucocytes. Use of a new chemotaxis assay with Candida albicans as gradient source. Exp Cell Res. 1978 Jan;111(1):191–203. doi: 10.1016/0014-4827(78)90249-5. [DOI] [PubMed] [Google Scholar]
  2. BAKER R. D., HAUGEN R. K. Tissue changes and tissue diagnosis in cryptococcosis; a study of 26 cases. Am J Clin Pathol. 1955 Jan;25(1):14–24. doi: 10.1093/ajcp/25.1.14. [DOI] [PubMed] [Google Scholar]
  3. Bitter-Suermann D., Hadding U., Schorlemmer H. U., Limbert M., Dierich M., Dukor P. Activation by some T-independent antigens and B cell mitogens of the alternative pathway of the complement system. J Immunol. 1975 Aug;115(2):425–430. [PubMed] [Google Scholar]
  4. Denning T. J., Davies R. R. Candida albicans and the chemotaxis of polymorphonuclear neutrophils. Sabouraudia. 1973 Nov;11(3):210–221. [PubMed] [Google Scholar]
  5. Diamond R. D., Bennett J. E. Prognostic factors in cryptococcal meningitis. A study in 111 cases. Ann Intern Med. 1974 Feb;80(2):176–181. doi: 10.7326/0003-4819-80-2-176. [DOI] [PubMed] [Google Scholar]
  6. Diamond R. D., May J. E., Kane M. A., Frank M. M., Bennett J. E. The role of the classical and alternate complement pathways in host defenses against Cryptococcus neoformans infection. J Immunol. 1974 Jun;112(6):2260–2270. [PubMed] [Google Scholar]
  7. Edwards M., Stark J. M. The ability of smooth and rough strains of Streptococcus pneumoniae to activate human complement by the alternative pathway. J Med Microbiol. 1978 Feb;11(1):7–14. doi: 10.1099/00222615-11-1-7. [DOI] [PubMed] [Google Scholar]
  8. Farmer S. G., Komorowski R. A. Histologic response to capsule-deficient Cryptococcus neoformans. Arch Pathol. 1973 Dec;96(6):383–387. [PubMed] [Google Scholar]
  9. GADEBUSCH H. H. Natural host resistance to infection with Cryptococcus neoformans. I. The effect of the properdin system on the experimental disease. J Infect Dis. 1961 Sep-Oct;109:147–153. doi: 10.1093/infdis/109.2.147. [DOI] [PubMed] [Google Scholar]
  10. Galgiani J. N., Isenberg R. A., Stevens D. A. Chemotaxigenic activity of extracts from the mycelial and spherule phases of Coccidioides immitis for human polymorphonuclear leukocytes. Infect Immun. 1978 Sep;21(3):862–865. doi: 10.1128/iai.21.3.862-865.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Götze O., Müller-Eberhard H. J. The C3-activator system: an alternate pathway of complement activation. J Exp Med. 1971 Sep 1;134(3 Pt 2):90s–108s. [PubMed] [Google Scholar]
  12. Kozel T. R., Cazin J. Nonencapsulated Variant of Cryptococcus neoformans I. Virulence Studies and Characterization of Soluble Polysaccharide. Infect Immun. 1971 Feb;3(2):287–294. doi: 10.1128/iai.3.2.287-294.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kozel T. R., Mastroianni R. P. Inhibition of phagocytosis by cryptococcal polysaccharide: dissociation of the attachment and ingestion phases of phagocytosis. Infect Immun. 1976 Jul;14(1):62–67. doi: 10.1128/iai.14.1.62-67.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kozel T. R. Non-encapsulated variant of Cryptococcus neoformans. II. Surface receptors for cryptococcal polysaccharide and their role in inhibition of phagocytosis by polysaccharide. Infect Immun. 1977 Apr;16(1):99–106. doi: 10.1128/iai.16.1.99-106.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Macher A. M., Bennett J. E., Gadek J. E., Frank M. M. Complement depletion in cryptococcal sepsis. J Immunol. 1978 May;120(5):1686–1690. [PubMed] [Google Scholar]
  16. Martin A., Lachmann P. J., Halbwachs L., Hobart M. J. Haemolytic diffusion plate assays for factors B and D of the alternative pathway of complement activation. Immunochemistry. 1976 Apr;13(4):317–324. doi: 10.1016/0019-2791(76)90341-4. [DOI] [PubMed] [Google Scholar]
  17. McGaw T. G., Kozel T. R. Opsonization of Cryptococcus neoformans by human immunoglobulin G: masking of immunoglobulin G by cryptococcal polysaccharide. Infect Immun. 1979 Jul;25(1):262–267. doi: 10.1128/iai.25.1.262-267.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Mitchell T. G., Friedman L. In vitro phagocytosis and intracellular fate of variously encapsulated strains of Cryptococcus neoformans. Infect Immun. 1972 Apr;5(4):491–498. doi: 10.1128/iai.5.4.491-498.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Peterson P. K., Kim Y., Wilkinson B. J., Schmeling D., Michael A. F., Quie P. G. Dichotomy between opsonization and serum complement activation by encapsulated staphylococci. Infect Immun. 1978 Jun;20(3):770–775. doi: 10.1128/iai.20.3.770-775.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Quinn P. H., Crosson F. J., Jr, Winkelstein J. A., Moxon E. R. Activation of the alternative complement pathway by Haemophilus influenzae type B. Infect Immun. 1977 Apr;16(1):400–402. doi: 10.1128/iai.16.1.400-402.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Ray T. L., Wuepper K. D. Activation of the alternative (properdin) pathway of complement by Candida albicans and related species. J Invest Dermatol. 1976 Dec;67(6):700–703. doi: 10.1111/1523-1747.ep12598581. [DOI] [PubMed] [Google Scholar]
  22. Weeks B. A., Escobar M. R., Hamilton P. B., Fueston V. M. Chemotaxis of polymorphonuclear neutrophilic leukocytes by mannan-enriched preparations of Candida albicans. Adv Exp Med Biol. 1976;73(PT-A):161–169. doi: 10.1007/978-1-4684-3297-8_15. [DOI] [PubMed] [Google Scholar]
  23. Wilkinson B. J., Peterson P. K., Quie P. G. Cryptic peptidoglycan and the antiphagocytic effect of the Staphylococcus aureus capsule: model for the antiphagocytic effect of bacterial cell surface polymers. Infect Immun. 1979 Feb;23(2):502–508. doi: 10.1128/iai.23.2.502-508.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Winkelstein J. A., Bocchini J. A., Jr, Schiffman G. The role of the capsular polysaccharide in the activation of the alternative pathway by the pneumococcus. J Immunol. 1976 Feb;116(2):367–370. [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES